<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03725566</url>
  </required_header>
  <id_info>
    <org_study_id>2017L02087</org_study_id>
    <nct_id>NCT03725566</nct_id>
  </id_info>
  <brief_title>JY028 Single Vitreous Injection in a Phase 1 Clinical Trial in nAMD Patients</brief_title>
  <official_title>Phase I Clinical Trial of Recombinant Humanized Anti-vegf Monoclonal Antibody Single Vitreous Injection for Safety, Tolerance, PK and Pharmacodynamics in nAMD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tongren Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tongren Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I clinical trial on safety, tolerance, pharmacokinetics (PK) and pharmacodynamics of
      recombinant human anti-VEGF monoclonal antibody injection in patients with neovascular (wet)
      age-related macular degeneration
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Test drug:Recombinant humanized anti VEGF monoclonal antibody injection; Research Phase:Phase
      I; Subjects:Subjects with neovascular (wet) age-related macular degeneration; Number of
      Subjects:24; Trial design:Single center, non randomized, open, single arm, single dose, dose
      escalation; Research objective:to rearch the safety and tolerance of JY028 injection;to
      rearch PK of JY028 injection;to observe the efficacy of JY028 in the treatment of nAMD;to
      rearch the relationship between plasma VEGF concentration and JY028 concentration. to rearch
      immunogenicity of JY028;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 22, 2018</start_date>
  <completion_date type="Anticipated">May 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>JY028 related incidence of ocular and systemic adverse events and serious adverse events</measure>
    <time_frame>13 weeks</time_frame>
    <description>JY028 related incidence of ocular and systemic adverse events and serious adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>13 weeks</time_frame>
    <description>Maximum blood drug concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>13 weeks</time_frame>
    <description>Peak time of blood drug concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BCVA</measure>
    <time_frame>13 weeks</time_frame>
    <description>The best corrected visual acuity change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t„ÄÅAUCinf</measure>
    <time_frame>13 weeks</time_frame>
    <description>The area under the plasma concentration time curves</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant humanized anti-VEGF monoclonal antibody injection 0.625mg/1.25mg/2.0mg/2.5mg by intravitreous injection,day 1 in the first month;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental</intervention_name>
    <description>Recombinant humanized anti-VEGF monoclonal antibody injection 0.625mg/1.25mg/2.0mg/2.5mg by intravitreous injection,day 1 in the first month;</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>intravitreous injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. The patient volunteered to participate and signed the informed consent 2. No more than
        50 years of age and less than 75 years of age, male or female 3. Diagnosed as nAMD 4. The
        optimal corrected visual acuity of the target eye ETDRS should be no more than 50 letters,
        and the optimal corrected visual acuity of the opposite eye should be no more than 34
        letters 5. The target eye pressure is no more than 25mmHg, which can be controlled by drugs
        6. A normal coagulation function: the platelet count is 100 x 10 ^ 9-300x 10^10 / L,
        thrombin time, prothrombin time within the normal range.

        -

        Exclusion Criteria:

          1. Choroid polypoid angiopathy (PCV)

          2. There are other obvious eye diseases/conditions (such as diabetic retinopathy,
             cataract, abnormal eyelid, uncontrolled glaucoma, eye active inflammation, etc.)

          3. CNV caused by other causes other than nAMD, such as diabetic retinopathy, vascular
             stripe disease, ocular histoplasmosis, case myopia, trauma, etc

          4. The target eye has received any intraocular surgery or laser therapy within 3 months
             prior to enrollment

          5. Any eye treated with antiangiogenic drugs within 3 months prior to baseline visit

          6. Patients with active eye infections, such as conjunctivitis, keratitis, sclerotic,
             blepharitis, endophthalmitis or uveitis

          7. Persons with a history of myocardial infarction and/or cerebral infarction or other
             active or acute cardiovascular diseases

          8. HIV antibody/hiv-p24 antigen, any of the positive subjects in the treponema pallidum
             antibody

          9. Active HBsAg carriers (conditions must be met: HBsAg positive, HBV DNA positive, ALT
             higher than normal upper limit)

         10. Patients with HCV (the following conditions must be met: lgM positive anti-hcv
             antibody, ALT higher than the upper limit of normal value)

         11. Fluorescein sodium allergy

         12. Allergy to anti-vegf monoclonal antibodies or humanized monoclonal antibodies

         13. Patients who participated in other clinical trials within 3 months

         14. Patients who took NSAIDs and aspirin or other anticoagulant or platelet drugs within 1
             month before enrollment

         15. An unhealed wound, ulcer, fracture, or other related medical condition

         16. Patients with uncontrollable hypertension, with systolic blood pressure of &gt; 140mmHg
             and diastolic blood pressure of &gt; 90mmHg

         17. Patients with uncontrollable clinical diseases or problems (such as serious mental,
             neurological, cardiovascular, respiratory and other systemic diseases and malignant
             tumors)

         18. Pregnant and lactating women and those who cannot take contraceptive measures

         19. According to the researcher, it is not suitable for the candidate -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>xiu li zhao, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tongren Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Tongren Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 20, 2018</study_first_submitted>
  <study_first_submitted_qc>October 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2018</study_first_posted>
  <last_update_submitted>October 30, 2018</last_update_submitted>
  <last_update_submitted_qc>October 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>New vascular macular degeneration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

